Part 4 of 6—How Do Celgene’s Revlimid Policies Affect 340B Hospitals and Patient Care?
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health system and hospital representatives interviewed for this series declined to be identified, explaining that they did not want to jeopardize their relationships with BMS. Nearly all declined to be quoted.)
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health system and hospital representatives interviewed for this series declined to be identified, explaining that they did not want to jeopardize their relationships with BMS. Nearly all declined to be quoted.)
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
